|Table of Contents|

Analysis of clinical features of secondary tumors in nine patients with acute myeloid leukemia after treatment

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 03
Page:
514-518
Research Field:
Publishing date:

Info

Title:
Analysis of clinical features of secondary tumors in nine patients with acute myeloid leukemia after treatment
Author(s):
JIAO Yang1; WANG Hao1; BI Lijun2; XU Qingxia1
1.Department of Clinical Laboratory,The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,Zhengzhou Key Laboratory of Digestive Tumor Markers,Henan Zhengzhou 450008,China；2.Institute of Biophysics,Chinese Academy of Scineces,Guangdong Foshan 528000,China.
Keywords:
acute myeloid leukemia; after treatment; second tumor; clinical characteristic
PACS:
R733.71
DOI:
10.3969/j.issn.1672-4992.2024.03.022
Abstract:
Objective:To investigate the clinical characteristics of the second tumor in patients with acute myeloid leukemia(AML) after treatment.Methods:The laboratory and clinical data of 9 patients with second tumor after primary AML treatment in the Affiliated Cancer Hospital of Zhengzhou University from January 2012 to December 2021 were retrospectively analyzed.The laboratory and clinical data were obtained by consulting the electronic medical record system and laboratory data management system.SPSS 25.0 software was used for data analysis.Results:Among the 9 patients with AML,8 patients achieved CR after induction chemotherapy,1 patient did not achieve CR after induction chemotherapy,and CRi after HSCT.The second tumors of the 9 patients were ovarian sex cord stromal tumor,lung squamous cell carcinoma,colon cancer,B-cell lymphoma,colorectal adenocarcinoma,malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma,thyroid micropapillary carcinoma,neuroendocrine tumor,and renal clear cell carcinoma.The diagnostic interval between the two types of tumors in 9 patients was 12.0(5.0～24.5) months.At the end of follow-up,4 patients were in stable treatment,3 patients died of second tumor progression,2 patients died of leukemia recurrence,and the median OS of 9 patients was 51 months,excluding 3 patients with M3,the median OS was 34 months.Conclusion:Patients with AML who develop a second tumor after treatment should be vigilant in clinical work,and regular blood routine,tumor markers,genes and imaging examinations should be performed before and after treatment.On the one hand,it can assess the disease,and on the other hand,it helps to detect the second tumor early.

References:

[1]张世媛,毛霞,黄亮.CAR-T治疗难治/复发B细胞肿瘤患者后继发第二肿瘤2例并文献复习［J］.中国癌症防治杂志,2021,13(4):376-379. ZHANG SY,MAO X,HUANG L.Second tumor after CAR-T therapy in refractory/relapsed B-cell tumor:two cases study and literature review［J］.Chinese Journal of Oncology Prevention and Treatment,2021,13(4):376-379.
[2]SAEED S,HALAPPA NAGARAJ R,GREZENKO H,et al.FLT3-ITD mutation and allogeneic stem cell transplantation in acute myeloid leukemia:a case study［J］.Cureus,2023,26;15(7):e42504.
[3]SONG X,PENG Y,WANG X,et al.The stimulator of interferon genes(STING) agonists for treating acute myeloid leukemia(AML):current knowledge and future outlook［J］.Clin Transl Oncol,2023,25(6):1545-1553.
[4]米瑞华,党慧兵,陈玲,等.急性髓系白血病合并同时性多原发实体瘤12例临床特征分析［J］.中华医学杂志,2020,100(42):3323-3327. MI RH,DANG XB,CHEN L,et al.Clinical analysis of 12 cases of acute myeloid leukemia complicated with synchronous primary solid tumor［J］.National Medical Journal of China,2020,100(42):3323-3327.
[5]KHOURY JD,SOLARY E,ABLA O,et al.The 5th edition of the world health organization classification of haematolymphoid tumours:myeloid and histiocytic/dendritic neoplasms［J］.Leukemia,2022,36(7):1703-1719.
[6]沈悌,赵永强,周道斌,等.血液病诊断及疗效标准(4版)［M］.北京:科学出版社,2018:97-109. SHEN T,ZHAO YQ,ZHOU DB,et al.Hematological diagnosis and therapeutic criteria(Version 4)［M］.Beijing:Science Press,2018:97-109.
[7]乐晨琴,周欣毅,杨琦,等.合并结直肠恶性肿瘤的多原发恶性肿瘤临床流行病学特点及病理特征分析［J］.中华肿瘤杂志,2022,44(8):888-892. LE CQ,ZHOU XY,YANG Q,et al.Analysis of clinical epidemiology and pathological characteristics of multiple primary malignant tumors accompanied with colorectal malignant tumors［J］.Chinese Journal of Oncology,2022,44(8):888-892.
[8]ZHAI C,CAI Y,LOU F,et al.Multiple primary malignant tumors- a clinical analysis of 15321 patients with malignancies at a single center in China［J］.J Cancer,2018,9(16):2795-2801.
[9]吕佳铭,熊华才,吴波,等.138例首发于消化系统的多原发癌临床分析［J］.中华肿瘤杂志,2018,40(2):147-150. LV JM,XIONG HC,WU B,et al.Clinical analysis of 138 multiple primary cancers diagnosed of digestive system malignant tumor initially［J］.Chinese Journal of Oncology,2018,40(2):147-150.
[10]OSSENKOPPELE G,MONTESINOS P.Challenges in the diagnosis and treatment of secondary acute myeloid leukemia［J］.Crit Rev Oncol Hematol,2019,138:6-13.
[11]HEGEMANN NS,SCHLESINGER-RAAB A,GANSWINDT U,et al.Risk of second cancer following radiotherapy for prostate cancer:a population-based analysis［J］.Radiat Oncol,2017,12(1):2.
[12]TANG L,WU J,LI CG,et al.Characterization of immune dysfunction and identification of prognostic immune-related risk factors in acute myeloid leukemia［J］.Clin Cancer Res,2020,26(7):1763-1772.
[13]CORTES JE,GUTZMER R,KIERAN MW,et al.Hedgehog signaling inhibitors in solid and hematological cancers［J］.Cancer Treat Rev,2019,76:41-50.
[14]KAIRA K,NARUSE I,SHINOMIYA S,et al.Occurrence of hematological malignancy in long-term survivors with advanced thymic cancer［J］.In Vivo,2020,34(3):1511-1513.
[15]任维肖,陈秀花,任颜,等.急性早幼粒细胞白血病治疗后继发急性髓系白血病部分分化型一例并文献复习［J］.白血病·淋巴瘤,2020,29(9):556-560. REN WX,CHEN XH,REN Y,et al.Secondary acute myeloid leukemia with partial differentiation following treatment of acute promyelocytic leukemia:report of one case and review of literature［J］.Journal of Leukemia and Lymphoma,2020,29(9):556-560.
[16]丁冰洁,刘柳,赵慧芳,等.急性早幼粒细胞白血病治疗后转换为急性髓系白血病M2一例并文献复习［J］.白血病·淋巴瘤,2019,28(12):766-768. DING BJ,LIU L,ZHAO HF,et al.Acute myeloid leukemia M2 transformation in acute promyelocytic leukemia after treatment:report of one case and review of literature［J］.Journal of Leukemia and Lymphoma,2019,28(12):766-768.
[17]ZIEGLER AK,ABEND M,PORT M,et al.Cumulative dosages of chemotherapy and radiotherapy exposure,and risk of secondary malignancies after allogeneic hematopoietic stem cell transplantation［J］.Bone Marrow Transplant,2019,54(4):635-640.

Memo

Memo:
National Natural Science Foundation of China（No.82203572）;国家自然科学基金项目（编号：82203572）;河南省医学科技攻关计划省部共建重点项目（编号：SBGJ202102070）
Last Update: 2023-12-29